- Home
- FINW vs CRBP Comparison
FINW vs CRBP Comparison
Compare FINW & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FINW
- CRBP
- Stock Information
- Founded
- FINW 1999
- CRBP 2009
- Country
- FINW United States
- CRBP United States
- Employees
- FINW N/A
- CRBP N/A
- Industry
- FINW Commercial Banks
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- FINW Finance
- CRBP Health Care
- Exchange
- FINW Nasdaq
- CRBP Nasdaq
- Market Cap
- FINW 242.1M
- CRBP 233.5M
- IPO Year
- FINW 2021
- CRBP N/A
- Fundamental
- Price
- FINW $19.08
- CRBP $10.44
- Analyst Decision
- FINW Buy
- CRBP Strong Buy
- Analyst Count
- FINW 3
- CRBP 9
- Target Price
- FINW $21.67
- CRBP $49.00
- AVG Volume (30 Days)
- FINW 13.2K
- CRBP 641.3K
- Earning Date
- FINW 10-29-2025
- CRBP 11-07-2025
- Dividend Yield
- FINW N/A
- CRBP N/A
- EPS Growth
- FINW N/A
- CRBP N/A
- EPS
- FINW 1.05
- CRBP N/A
- Revenue
- FINW $80,199,000.00
- CRBP N/A
- Revenue This Year
- FINW $72.14
- CRBP N/A
- Revenue Next Year
- FINW $47.30
- CRBP $220.00
- P/E Ratio
- FINW $18.24
- CRBP N/A
- Revenue Growth
- FINW 14.76
- CRBP N/A
- 52 Week Low
- FINW $13.49
- CRBP $4.64
- 52 Week High
- FINW $22.49
- CRBP $20.77
- Technical
- Relative Strength Index (RSI)
- FINW 54.44
- CRBP 30.02
- Support Level
- FINW $18.51
- CRBP $11.59
- Resistance Level
- FINW $19.80
- CRBP $18.11
- Average True Range (ATR)
- FINW 0.67
- CRBP 1.28
- MACD
- FINW 0.16
- CRBP -1.00
- Stochastic Oscillator
- FINW 70.29
- CRBP 5.49
About FINW FinWise Bancorp
FinWise Bancorp is an independent bank that provides a full range of banking services to individual and corporate customers. The bank's primary source of revenue is from loans, including Small Business Administration, commercial, commercial real estate, residential real estate, and consumer. The Bank has also established Strategic Programs with various third-party loan origination platforms that use technology to streamline the origination of unsecured consumer and secured or unsecured business loans to borrowers within certain approved credit profiles.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.